Authors: Kimberley Tran (M.A.), Nigel SB Rawson (Ph.D.), Brett J Skinner (Ph.D.)
This study examined how health technology assessment (HTA) decisions affect access to new drug treatments for mental health in Canada’s public drug plans, and discusses the results in the context of the societal economic burden of mental illness and quality of life impacts on people living with mental illness and their caregivers. The drugs studied included all New Drug Submissions (NDSs) that received a Notice of Compliance (NOC) from Health Canada and were reviewed by the Common Drug Review (CDR) between 2004 and 2015. Data were obtained from Health Canada, the Canadian Agency for Drugs and Technologies in Health (CADTH), QuintilesIMS and Statistics Canada.
Contains consecutive English and French language versions.
Open Access Sponsorship
Free public access to this study was made possible by funding provided by Lundbeck Canada Inc.
